your market intelligence analyst
Search Results
44 results
Your search is now limited to «Tuberculosis» expert search.
European Respiratory Journal 12/04/2019 19:05
Despite all our efforts, the disease burden of tuberculosis (TB) is not falling fast enough to reach the 2030 milestone of the End TB strategy [1]. Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis, with low treatment success rates [1]. The repurposed drug linezolid has emerged as a core drug in MDR-TB treatment regimens [2, 3], despite its toxicity, e.g. anaemia, peripheral neuropathy and gastrointestinal disorders, optic neuritis, and thrombocytopenia [4, 5]. Currently, linezolid is used off-label, as part of Group A "Medicines to be prioritised" of the World Health Organization (WHO) MDR-TB treatment guideline [2] and in several large trials [6], such as the NIX-TB and END-TB trials.
More from European Respiratory Journal: 11/25/2019 07:43
Condition : Pulmonary Tuberculosis Interventions : Drug: TBA-7371; Drug: HRZE Sponsor : Bill & Melinda Gates Medical Research Institute Not yet recruiting.
More from
PubMed News (NIH) 11/08/2019 23:00
Contributors : Artem Grigorov ; Taiana Kondratieva ; Konstantin Majorov ; Tatyana Azhikina ; Alexander S Apt Series Type : Expression profiling by high throughput sequencing ; Non-coding RNA profiling by high throughput sequencing Organism : Mycobacterium tuberculosis. This study was conducted to descripe transcriptomic changes of M.tuberculosis during neutrophil infection.
More from PubMed News (NIH):
Lancet 11/07/2019 20:17
We read with interest the Comment by Jagat Prakash Nadda.1 The measures being taken to overcome the challenges affecting the Tuberculosis Control Programme in India are truly noteworthy.
More from Lancet:
Get a Sample Copy of the Report at The Global Tuberculosis Diagnostics market 2019 research provides a basic overview of the industry including definitions, classifications, applications, and industry chain structure.
More from Middle East North Africa Financial Network (MENAFN):
Org. Biomol. Chem. , 2019, Advance Article DOI : 10.1039/C9OB02222H, Paper. Open Access. This article is licensed under a. Collette S. Guy, Kathryn Murray, Matthew I. Gibson, Elizabeth Fullam Dimeric benzoboroxoles that are covalently linked by a short scaffold enhance selective anti-tubercular activity. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed © The Royal Society of Chemistry.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications